Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Clinical trial NCT02962414 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02962414
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-23
- Primary completion
- 2026-12-30
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.